HHS Public Access Author manuscript Author Manuscript
Brain Inj. Author manuscript; available in PMC 2017 July 26. Published in final edited form as: Brain Inj. 2016 ; 30(10): 1266–1270. doi:10.1080/02699052.2016.1187289.
ICU sedation with dexmedetomidine after severe traumatic brain injury Stephen S. Humble, BS1, Laura D. Wilson, MS, CCC-SLP2,4, Taylor C. Leath, MPH1, Matthew D. Marshall, PharmD3, Daniel Z. Sun, MD5, Pratik P. Pandharipande, MD, MSCI6,7, and Mayur B. Patel, MD, MPH, FACS1,7 1Vanderbilt
Author Manuscript
University School of Medicine, Division of Trauma & Surgical Critical Care, Departments of Surgery and Neurosurgery, Nashville, TN
2Vanderbilt
University School of Medicine, Department of Hearing and Speech Sciences, Nashville, TN 3Vanderbilt 4The
University School of Medicine, Department of Pharmaceutical Services, Nashville, TN
University of Tulsa, Department of Communication Sciences and Disorders, Tulsa, OK
5Cleveland
Clinic, Department of Urology, Glickman Urological Kidney Institute, Cleveland, Ohio
6Vanderbilt
University School of Medicine, Departments of Anesthesiology, Surgery, and Biomedical Informatics, Nashville, TN
7Veterans
Author Manuscript
Affairs (VA) Tennessee Valley Healthcare System, Nashville VA Medical Center, Nashville, TN
Abstract Objective—To comprehensively describe the use of dexmedetomidine in a single institutional series of adult ICU patients with severe TBI. We describe the dexmedetomidine dosage and infusion times, as well as the physiological parameters, neurological status, and daily narcotic requirements before, during, and after dexmedetomidine infusion. Methods—We identified 85 adult patients with severe TBI who received dexmedetomidine infusions in the Trauma ICU at Vanderbilt University Medical Center between 2006 and 2010. Demographic, hemodynamic, narcotic use, and sedative use data were systematically obtained from the medical record and analyzed for changes associated with dexmedetomidine infusion.
Author Manuscript
Results—During infusion with dexmedetomidine, narcotic and sedative use decreased significantly (p
Brain Inj. Author manuscript; available in PMC 2017 July 26. Published in final edited form as: Brain Inj. 2016 ; 30(10): 1266–1270. doi:10.1080/02699052.2016.1187289.
ICU sedation with dexmedetomidine after severe traumatic brain injury Stephen S. Humble, BS1, Laura D. Wilson, MS, CCC-SLP2,4, Taylor C. Leath, MPH1, Matthew D. Marshall, PharmD3, Daniel Z. Sun, MD5, Pratik P. Pandharipande, MD, MSCI6,7, and Mayur B. Patel, MD, MPH, FACS1,7 1Vanderbilt
Author Manuscript
University School of Medicine, Division of Trauma & Surgical Critical Care, Departments of Surgery and Neurosurgery, Nashville, TN
2Vanderbilt
University School of Medicine, Department of Hearing and Speech Sciences, Nashville, TN 3Vanderbilt 4The
University School of Medicine, Department of Pharmaceutical Services, Nashville, TN
University of Tulsa, Department of Communication Sciences and Disorders, Tulsa, OK
5Cleveland
Clinic, Department of Urology, Glickman Urological Kidney Institute, Cleveland, Ohio
6Vanderbilt
University School of Medicine, Departments of Anesthesiology, Surgery, and Biomedical Informatics, Nashville, TN
7Veterans
Author Manuscript
Affairs (VA) Tennessee Valley Healthcare System, Nashville VA Medical Center, Nashville, TN
Abstract Objective—To comprehensively describe the use of dexmedetomidine in a single institutional series of adult ICU patients with severe TBI. We describe the dexmedetomidine dosage and infusion times, as well as the physiological parameters, neurological status, and daily narcotic requirements before, during, and after dexmedetomidine infusion. Methods—We identified 85 adult patients with severe TBI who received dexmedetomidine infusions in the Trauma ICU at Vanderbilt University Medical Center between 2006 and 2010. Demographic, hemodynamic, narcotic use, and sedative use data were systematically obtained from the medical record and analyzed for changes associated with dexmedetomidine infusion.
Author Manuscript
Results—During infusion with dexmedetomidine, narcotic and sedative use decreased significantly (p
